Results Presented at Heart Rhythm Society from ASA Plavix Study Evaluating Boston Scientific Left Atrial Appendage Closure Device NATICK and BOSTON, Mass., Boston Scientific Corporation announces ...
Milestone Marks Next Step Toward FDA Submission for Stroke Reduction Device for Patients with Atrial Fibrillation NATICK, Mass. -- Boston Scientific Corporation has completed enrollment in the PREVAIL ...
MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...
(Updated) SAN FRANCISCO, California — Preliminary data from the PREVAIL study of the Watchman (AtriTech/Boston Scientific) device for the prevention of stroke and systemic embolism in patients with ...
The idea of implanting a device inside the heart to block blood flow may sound counterintuitive, but in the case of left atrial appendage closure devices like Boston Scientific’s Watchman FLX, that ...
CHICAGO – Results from the EWOLUTION registry show that Boston Scientific Corp.'s Watchman Left Atrial Appendage (LAA) Closure device was effective in stroke reduction for patients with non-valvular ...
Boston Scientific has won a nod from FDA for the latest generation of the Watchman Left Atrial Appendage Closure (LAAC) technology. Dubbed the Watchman FLX, the technology is designed to advance ...
Findings from a trial led by Cleveland Clinic show that patients with atrial fibrillation undergoing a transcatheter aortic valve replacement (TAVR) at the same time as a left atrial appendage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results